MAO-Hemmer als Behandlungsoption der therapieresistenten Depression

S. Köhler; L. A. Stöver; T. Bschor

doi:10.1055/s-0034-1365945

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2014; 82(4): 228-238
DOI: 10.1055/s-0034-1365945

Fort- und Weiterbildung

MAO-Hemmer als Behandlungsoption der therapieresistenten Depression

Anwendung, Wirksamkeit und BesonderheitenMAO-Inhibitors – A Treatment Option for Treatment Resistant DepressionApplication, Efficacy and Characteristics

S. Köhler

¹Klinik für Psychiatrie und Psychotherapie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin

,

L. A. Stöver

¹Klinik für Psychiatrie und Psychotherapie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin

,

T. Bschor

²Abteilung für Psychiatrie der Schlosspark-Klinik Berlin und Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Jama 2003; 289: 3095-3105
2 Bschor T. Therapy-resistant depression. Expert Rev Neurother 2010; 10: 77-86
3 Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
4 Adli M, Pilhatsch M, Bauer M et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry 2008; 41: 252-257
5 Lewitzka U. Irreversible MAO-Hemmer. In: Bschor T, Hrsg Behandlungsmanual therapieresistente Depression Pharmakotherapie – somatische Therapieverfahren – Psychotherapie. Stuttgart: Kohlhammer; 2008: 102-113
6 Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004; 11: 2033-2043
7 Crane GE. The psychiatric side-effects of iproniazid. Am J Psychiatry 1956; 112: 494-501
8 Laux G, Becker T, Müller U. Monoaminoxidasehemmer. In: Riederer P, Laux G, Pöldinger W, Hrsg Neuro-Psychopharmaka – Ein Therapiehandbuch Band 3 Wien. New York: Springer; 2002: 489-507
9 Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13: 855-870
10 Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12: 185-219
11 Gordon MN, Muller CD, Sherman KA et al. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav 1999; 63: 501-506
12 Baker GB, Coutts RT, McKenna KF et al. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci 1992; 17: 206-214
13 Laux G, Volz HP, Möller HJ. Newer and older monoamine oxidase inhibitors. A comparative profile. CNS Drugs 1995; 3: 145-158
14 Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20: 226-247
15 Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001; 57: 161-178
16 Himmelhoch JM, Thase ME, Mallinger AG et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916
17 Thase ME, Frank E, Mallinger AG et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992; 53: 5-11
18 Thase ME, Mallinger AG, McKnight D et al. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-198
19 Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressions. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 155-158
20 Volz HP, Faltus F, Magyar I et al. Brofaromine in treatment-resistant depressed patients – a comparative trial versus tranylcypromine. J Affect Disord 1994; 30: 209-217
21 McGrath PJ, Stewart JW, Fava M et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1531-1541 quiz 1666
22 Rossel L, Moll E. Moclobemide versus tranylcypromine in the treatment of depression. Acta Psychiatr Scand Suppl 1990; 360: 61-62
23 Heinze G, Rossel L, Gabelic I et al. Double-blind comparison of moclobemide and tranylcypromine in depression. Pharmacopsychiatry 1993; 26: 240-245
24 Rapaport MH, Thase ME. Translating the evidence on atypical depression into clinical practice. J Clin Psychiatry 2007; 68: e11
25 McGrath PJ, Stewart JW, Harrison W et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987; 23: 169-172
26 Liebowitz MR, Quitkin FM, Stewart JW et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45: 129-137
27 Quitkin FM. Depression With Atypical Features: Diagnostic Validity, Prevalence, and Treatment. Prim Care Companion J Clin Psychiatry 2002; 4: 94-99
28 McGrath PJ, Stewart JW, Nunes EV et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993; 150: 118-123
29 Laux G, Ulrich S. Tranylcypromin. Psychopharmakotherapie 2006; 13: 130-140
30 Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387-400
31 Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985; 46: 206-209
32 Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. J Clin Psychiatry 2012; (Suppl. 01) 73
33 Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 2004; 10: 239-248
34 el-Ganzouri AR, Ivankovich AD, Braverman B et al. Monoamine oxidase inhibitors: should they be discontinued preoperatively?. Anesth Analg 1985; 64: 592-596
35 Naguib M, Koorn R. Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. CNS Drugs 2002; 16: 229-247
36 Briggs NC, Jefferson JW, Koenecke FH. Tranylcypromine addiction: a case report and review. J Clin Psychiatry 1990; 51: 426-429
37 Walker SE, Shulman KI, Tailor SA et al. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol 1996; 16: 383-388
38 Köberle U, Bschor T. Dysarthrie als serotonerge Nebenwirkung durch Interaktion zwischen Duloxetin und Tramadol. Psychopharmakotherapie 2007; 14: 82-84
39 Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42: 1578-1583
40 DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression (2009) S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression, 1. Auflage 2009. DGPPN, ÄZQ, AWMF – Berlin, Düsseldorf 2009. Internet: www.dgppn.de, www.versorgungsleitlinien.de, www.awmf-leitlinien.de
41 Vandenberg CM. MAOIs and transdermal delivery. J Clin Psychiatry 2012; 73: e28
42 Bschor T. Monoaminooxidase und -Hemmer. In: Affektive Störungen XXS pocket. Grünwald: Börm Bruckmeier Verlag; ; 2009; 66
43 Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol 2011; 31: 66-74
44 Grossman E, Messerli FH, Grodzicki T et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?. JAMA 1996; 276: 1328-1331